Multiple GPRC5D Agents For Myeloma Raise Questions On Positioning
Bispecifics Could Be Better For More Vulnerable Patients
J&J’s talquetamab is in the lead among bispecific antibodies, while Roche and BMS are not far behind. Presentations at ASH sparked discussion on how to position them in treatment.
